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PMH34
CHARACTERIZATION AND ASSESSMENT OF 
DEPRESSION IN A CHRONIC NON-MALIGNANT 
PAIN POPULATION USING TWO DIFFERENT 
METHODOLOGIES IN A CLAIMS DATABASE
Mody SH1, Hsu AY2, Dodd SL1
1Janssen Pharmaceutica, Titusville, NJ, USA; 2Janssen Research 
Foundation, Titusville, NJ, USA
There are numerous methods for identifying patients
with depression from claims databases. Different indica-
tors for disease may lead to different results in both pop-
ulation and health resource utilization. OBJECTIVE: To
evaluate the economic impact of depression in a chronic
non-malignant pain (CNMP) population using two dif-
ferent indicators for depression. METHODS: The 1995–
1997 MarketScan claims database was used to identify a
CNMP cohort. Patients were labeled with CNMP if two
or more prescriptions for a long-acting opioid were given
in any one-year period. Depression was categorized in
this cohort using two different methods: ICD-9-CM diag-
nosis or antidepressant claim. Antidepressant usage (1997
numbers) was categorized as patients having a claim for
TCAs (n  157), SSRIs (n  143), other antidepressants
(n  36), combination of antidepressants (n  236), or
no claims (n  233). Resource utilization was measured
using outpatient, inpatient, and prescription costs. RE-
SULTS: For the 1997 CNMP cohort, 805 subjects were
identified. Using ICD-9-CM diagnoses (depression n 
159, non-depression n  646), demographics between
the groups were similar, with the non-depression group
represented by a higher percentage of males (46% versus
35%). Average inpatient ($19,303 versus $11,419), out-
patient ($12,665 versus $7738), prescription ($6486 ver-
sus $4548), and total ($38,454 versus $23,705) costs
were all higher for the CNMP group diagnosed with de-
pression. Similar values were also derived from the 1995
(n  154) and 1996 (n  323) cohorts. Using the second
methodology (categorizing depression by antidepressant
usage) showed that the group not prescribed antidepres-
sants had the lowest overall cost utilizing the same 1997
cohort. However, in 1995 and 1996, the group taking no
antidepressants did not have the lowest costs in either of
these years. Categorizing patients through antidepressant
usage resulted in conflicting differences between the
groups. CONCLUSION: Characterization and assess-
ment of depression using different methodologies in a
claims database led to different results in both the popu-
lation identified as well as total costs.
PMH35
ECONOMIC OUTCOMES WITH NEWER 
ANTIDEPRESSANTS FOR THE TREATMENT OF 
DEPRESSION IN A COMMERCIALLY-INSURED 
POPULATION
Mukherjee R, Lian J, Hines P, Dezii C, Chen S, Scull R, Alter C
Bristol-Myers Squibb Company, Plainsboro, NJ, USA
OBJECTIVES: To evaluate whether nefazodone HCl’s
clinical attributes translate to depression-related eco-
nomic savings during the first six months of antidepres-
sant therapy, relative to bupropion, fluoxetine, paroxet-
ine, sertraline, and venlafaxine. METHODS: We screened
the pharmacy and medical claims for all members of a
large, geographically diverse managed care organization
who were prescribed an antidepressant for the diagnosis
of a depressive disorder during the period 1/95 through
6/98. Patients had initiated new episodes of antidepres-
sant therapy and were characterized by having no preex-
isting anxiolytic or sedative/hypnotic use. The six-month
window immediately following antidepressant initiation
was screened for two primary outcomes: depression-
related pharmacy cost and depression-related medical
cost (drawn from all medical services for which a diagno-
sis of depression was recorded). Depression-related phar-
macy cost was defined as the cost incurred by the payor
for the index antidepressant, as well as the costs for any
additional medications, such as anxiolytics, sedative/hyp-
notics, and low-dose older antidepressants. RESULTS: A
total of 1,961 antidepressant users satisfied our eligibility
criteria. The rate of concomitant medication utilization
among nefazodone users within six months of antide-
pressant initiation was nearly twofold lower (11.9%)
than with the other antidepressant treatment groups
(19.7%–27.9%). After adjusting for age, gender, and
prior total 4-month medical and pharmacy utilization us-
ing a multivariate regression analysis, nefazodone emerged
as a significant predictor of 6-month depression-related
pharmacy and medical cost savings. Nefazodone was as-
sociated with a cost reduction of $129 per patient, rela-
tive to non-nefazodone treatment (P  0.05). When com-
pared with nefazodone, each antidepressant treatment
group was associated with significant incremental 6-month
depression-related cost (P  0.05 for each comparison).
CONCLUSIONS: Nefazodone’s co-prescription rate was
approximately one-half that observed for fluoxetine, par-
oxetine, sertraline, venlafaxine, and bupropion. It was a
significant predictor of 6-month depression-related cost
savings to the payer.
PMH36
CONFORMANCE WITH ANTIPSYCHOTIC 
DRUG THERAPY GUIDELINES FOR TREATING 
SCHIZOPHRENIA IN THE CALIFORNIA 
MEDICAID (MEDI-CAL) PROGRAM
Luo M, McCombs JS, Shi L, Stimmel GL
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: To investigate the conformance of antipsy-
chotic drug therapy used to treat Medi-Cal patients with
schizophrenia to the Schizophrenia Patient Outcomes Re-
search Team (PORT) Treatment Recommendations and
to measure the impact of conformance on direct health
care costs. METHODS: Minimum effective doses and
completed therapy were defined based on the PORT Rec-
ommendations. We identified 2,567 patients with schizo-
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phrenia who were treated with antipsychotic medications
during their first post-treatment year. Data were drawn
from January 1987 to July 1996. Allowances were made
for titration and changes in therapy. Multiple logistic re-
gression models were used to identify factors affecting ti-
tration success and conformance. OLS regression models
were used to estimate the impact of the PORT conform-
ance on health care costs. RESULTS: Only 16.9% of the
2,567 patients treated with antipsychotic drugs achieved
conformance with PORT recommendations. Fewer than
50% patients achieved titration success on their initial
drugs, and the likelihood of PORT conformance in-
creased with initial dose. Patients who received at least
the minimum therapeutic dose on their first prescription
were 2.9 times more likely to achieve conformance than
patients who were prescribed less than 50% of the mini-
mum dose (P  0.0001). This odds ratio increased to 8.2
for patients treated initially at 3 times minimum dose
(P  0.0001). Patients treated initially with fluphenazine
were more likely to achieve conformance (odds ratio 
1.834, P  .0001), while thioridazine patients were less
likely to conform (0.436, P  0.0228). PORT conform-
ance was not associated with lower total costs ($2,543,
P  0.2453). CONCLUSION: In clinical practice, the
rate PORT conformance was low and conformance did
not significantly reduce total direct health care costs.
PMH37
EVALUATING HEALTHCARE RESOURCE 
UTILIZATION IN A POPULATION OF MIGRAINE 
PATIENTS USING SUMATRIPTAN AND NON-
SUMATRIPTAN PHARMACEUTICALS
Joish VN1, Cady PS2, Culbertson VL2, Delate T1
1College of Pharmacy, University of Arizona, Tucson, AZ, USA; 
2College of Pharmacy, Idaho State University, Pocatello, ID, 
USA
Previous investigations examining healthcare resource
utilization in patient populations have shown mi-
graineurs to consume significantly higher healthcare re-
sources versus non-migraineurs. However, there is a
dearth of healthcare resource utilization data within mi-
graine populations that examine a specific pharmaceuti-
cal’s impact on resource utilization. OBJECTIVE: To
compare healthcare resource and narcotic use in mi-
graineurs prescribed sumatriptan (oral, subcutaneous, or
nasal) versus migraineurs not prescribed sumatriptan.
DESIGN: A review of the 1998 Idaho Medicaid claims
database was performed. METHODS: Migraine patients
greater than four years of age were identified using two
inclusion criteria—physician diagnosed cases identified
by specific ICD-9-CM codes or patients prescribed mi-
graine-specific drugs. Comorbidity was identified using
specific diagnostic categories. Total healthcare resource
utilization, reported in dollars, was the sum amount paid
by Idaho Medicaid for all medications including anti-mi-
graine prescriptions, physician services, hospital services
(outpatient and inpatient), and emergency room services.
Logarithmic transformations were performed on depen-
dent variables. Linear regression modeling was per-
formed to determine predictors of resource utilization.
RESULTS: 498 migraineurs were identified. Patient char-
acteristics, including presence/absence of comorbidity,
showed no differences between the two groups. Mi-
graineurs prescribed sumatriptan had significantly lower
hospital visits (P  0.01), physician visits (P  0.01),
physician service fees (P  0.05), and fees paid for nar-
cotics (P  0.05). Sumatriptan prescription was not a sig-
nificant predictor of total healthcare utilization (P 
0.05), nor of narcotic use (P  0.05). CONCLUSIONS:
While migraine patients have higher healthcare resource
utilization, this study indicated that sumatriptan users
had significantly lower healthcare resource utilization
than non-sumatriptan users. However, we found that
sumatriptan use was not a significant predictor of higher
healthcare resource dollars.
PMH38
RESPONSE TO NEFAZODONE, CBASP, AND 
COMBINED THERAPY: IMPLICATIONS FOR 
CHRONIC DEPRESSION SEVERITY, 
FUNCTIONAL STATUS AND ECONOMIC 
OUTCOMES
Crown WH1, Berndt E2, Finkelstein S2, Russell J3, Ling D1, 
White A1, Koran L4, Dunner D5, Kocsis J6, Kornstein S7, 
Borian F8
1The MEDSTAT Group, Cambridge, MA, USA; 2Massachusetts 
Institute of Technology, Cambridge, MA, USA; 3University of 
Texas Medical Branch, Galveston, TX, USA; 4Stanford 
University School of Medicine, Stanford, CA, USA; 5University 
of Washington, Seattle, WA, USA; 6Cornell University Medical 
College, New York, NY, USA; 7Medical College of Virginia, 
Richmond, VA, USA; 8Bristol-Myers Squibb Company, 
Plainsboro, NJ, USA
Results from a recent trial suggest that combination of
nefazodone and Cognitive Behavioral Analysis System of
Psychotherapy (CBASP) is more efficacious than either
modality alone in the treatment of chronic depression.
OBJECTIVES: This analysis examines the relationship
between treatment modality, clinical measures of depres-
sion severity, measures of patient functioning, and eco-
nomic outcomes. METHODS: Outcomes data from the
12-week acute phase of a 12-site trial investigating the
therapeutic efficacy of nefazodone, CBASP and their
combination using symptom and functional metrics are
combined with medical claims data encompassing 1.4
million lives (MarketScan, The MEDSTAT Group) used
to attribute costs to clinical interventions. Economic ben-
efits of treatment are calculated by multiplying patient in-
come and proportional changes in functional capacity.
Modified versions of the Social Adjustment Scale (SAS),
SF-36, and L.I.F.E. are used to determine functional ca-
pacity. RESULTS: Work impairment improved signifi-
cantly for all groups, but is greatest for combination ther-
apy (P  0.02). This pattern is also observed for the
